» Articles » PMID: 38173369

Association of Measures of Glucose Metabolism with Colorectal Cancer Risk in Older Chinese: A 13-Year Follow-up of the Guangzhou Biobank Cohort Study-Cardiovascular Disease Substudy and Meta-Analysis

Overview
Specialty Endocrinology
Date 2024 Jan 4
PMID 38173369
Authors
Affiliations
Soon will be listed here.
Abstract

Backgruound: Abnormal glucose metabolism is a risk factor for colorectal cancer (CRC). However, association of glycosylated hemoglobin (HbA1c) with CRC risk remains under-reported. We examined the association between glycemic indicators (HbA1c, fasting plasma glucose, fasting insulin, 2-hour glucose, 2-hour insulin, and homeostasis model of risk assessment-insulin resistance index) and CRC risk using prospective analysis and meta-analysis.

Methods: Participants (n=1,915) from the Guangzhou Biobank Cohort Study-Cardiovascular Disease Substudy were included. CRC events were identified through record linkage. Cox regression was used to assess the associations of glycemic indicators with CRC risk. A meta-analysis was performed to investigate the association between HbA1c and CRC risk.

Results: During an average of 12.9 years follow-up (standard deviation, 2.8), 42 incident CRC cases occurred. After adjusting for potential confounders, the hazard ratio (95% confidence interval [CI]) of CRC for per % increment in HbA1c was 1.28 (95% CI, 1.01 to 1.63) in overall population, 1.51 (95% CI, 1.13 to 2.02) in women and 1.06 (95% CI, 0.68 to 1.68) in men. No significant association of other measures of glycemic indicators and baseline diabetes with CRC risk was found. Meta-analyses of 523,857 participants including our results showed that per % increment of HbA1c was associated with 13% higher risk of CRC, with the pooled risk ratio being 1.13 (95% CI, 1.01 to 1.27). Subgroupanalyses found stronger associations in women, colon cancer, Asians, and case-control studies.

Conclusion: Higher HbA1c was a significant predictor of CRC in the general population. Our findings shed light on the pathology of glucose metabolism and CRC, which warrants more in-depth investigation.

Citing Articles

Association between accelerated biological aging and colorectal cancer: a cross-sectional study.

Wang S, Wang K, Wang X Front Med (Lausanne). 2025; 12:1533507.

PMID: 40061382 PMC: 11885229. DOI: 10.3389/fmed.2025.1533507.


Associations between blood glucose and early- and late-onset colorectal cancer: evidence from two prospective cohorts and Mendelian randomization analyses.

Luo C, Luo J, Zhang Y, Lu B, Li N, Zhou Y J Natl Cancer Cent. 2024; 4(3):241-248.

PMID: 39281721 PMC: 11401484. DOI: 10.1016/j.jncc.2024.04.006.


Relationship Between Aspirin Use and Site-Specific Colorectal Cancer Risk Among Individuals With Metabolic Comorbidity.

An S, Gunathilake M, Lee J, Kim M, Oh J, Chang H J Korean Med Sci. 2024; 39(26):e199.

PMID: 38978486 PMC: 11231443. DOI: 10.3346/jkms.2024.39.e199.


Association of Measures of Glucose Metabolism with Colorectal Cancer Risk in Older Chinese: A 13-Year Follow-up of the Guangzhou Biobank Cohort Study-Cardiovascular Disease Substudy and Meta-Analysis (Diabetes Metab J 2024;48:134-45).

Wang S, Xu L Diabetes Metab J. 2024; 48(2):323-324.

PMID: 38556706 PMC: 10995488. DOI: 10.4093/dmj.2024.0085.


Association of Measures of Glucose Metabolism with Colorectal Cancer Risk in Older Chinese: A 13-Year Follow-up of the Guangzhou Biobank Cohort Study-Cardiovascular Disease Substudy and Meta-Analysis (Diabetes Metab J 2024;48:134-45).

Kim J Diabetes Metab J. 2024; 48(2):321-322.

PMID: 38556705 PMC: 10995497. DOI: 10.4093/dmj.2024.0070.

References
1.
Azizian-Farsani F, Abedpoor N, Sheikhha M, Gure A, Nasr-Esfahani M, Ghaedi K . Receptor for Advanced Glycation End Products Acts as a Fuel to Colorectal Cancer Development. Front Oncol. 2020; 10:552283. PMC: 7551201. DOI: 10.3389/fonc.2020.552283. View

2.
Deng H, Macfarlane D, Neil Thomas G, Lao X, Jiang C, Cheng K . Reliability and validity of the IPAQ-Chinese: the Guangzhou Biobank Cohort study. Med Sci Sports Exerc. 2008; 40(2):303-7. DOI: 10.1249/mss.0b013e31815b0db5. View

3.
Jiang C, Lam T, Lin J, Liu B, Yue X, Cheng K . An overview of the Guangzhou biobank cohort study-cardiovascular disease subcohort (GBCS-CVD): a platform for multidisciplinary collaboration. J Hum Hypertens. 2009; 24(2):139-50. DOI: 10.1038/jhh.2009.52. View

4.
Hartemink N, Boshuizen H, Nagelkerke N, Jacobs M, van Houwelingen H . Combining risk estimates from observational studies with different exposure cutpoints: a meta-analysis on body mass index and diabetes type 2. Am J Epidemiol. 2006; 163(11):1042-52. DOI: 10.1093/aje/kwj141. View

5.
Zhang Z, Zheng Z, Kan H, Song Y, Cui W, Zhao G . Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis. Diabetes Care. 2011; 34(10):2323-8. PMC: 3177711. DOI: 10.2337/dc11-0512. View